{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:28:13Z","timestamp":1762100893716},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,8]],"date-time":"2008-12-08T00:00:00Z","timestamp":1228694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s11940-009-0003-y","type":"journal-article","created":{"date-parts":[[2008,12,7]],"date-time":"2008-12-07T09:10:00Z","timestamp":1228641000000},"page":"18-23","source":"Crossref","is-referenced-by-count":13,"title":["Is botulinum toxin useful in treating headache? Yes"],"prefix":"10.1007","volume":"11","author":[{"given":"Avi","family":"Ashkenazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,8]]},"reference":[{"key":"3_CR1","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4","volume":"20","author":"M.F. Brin","year":"1997","unstructured":"Brin MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997, 20:S146\u2013S168.","journal-title":"Muscle Nerve"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","volume":"123","author":"W.J. Binder","year":"2000","unstructured":"Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669\u2013676.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/oso\/9780195326567.003.0032","volume-title":"Wolff\u2019s Headache and Other Head Pain","author":"A. Ashkenazi","year":"2007","unstructured":"Ashkenazi A, Levin M, Dodick DW: Peripheral procedures: nerve blocks, peripheral neurostimulation and botulinum toxin injections. In Wolff\u2019s Headache and Other Head Pain, edn 8. Edited by Silberstein SD, Lipton RB, Dodick DW. New York: Oxford University Press; 2007:767\u2013792."},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev.med.55.091902.104440","volume":"55","author":"A. Ashkenazi","year":"2004","unstructured":"Ashkenazi A, Silberstein SD: Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 2004, 55:505\u2013518.","journal-title":"Annu Rev Med"},{"key":"3_CR5","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1046\/j.1526-4610.2003.03027.x","volume":"43","author":"K.R. Aoki","year":"2003","unstructured":"Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43:S109\u2013S115.","journal-title":"Headache"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","volume":"44","author":"P.L. Durham","year":"2004","unstructured":"Durham PL, Cady R, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35\u201342.","journal-title":"Headache"},{"key":"3_CR7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","volume":"40","author":"S.D. Silberstein","year":"2000","unstructured":"Silberstein SD, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445\u2013450.","journal-title":"Headache"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10194-003-0049-2","volume":"4","author":"N. Barrientos","year":"2003","unstructured":"Barrientos N, Chana P: Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003, 4:146\u2013151.","journal-title":"J Headache Pain"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1468-2982.2004.00754.x","volume":"24","author":"S. Evers","year":"2004","unstructured":"Evers S, Vollmer-Haase J, Schwaag S, et al.: Botulinum toxin A in the prophylactic treatment of migraine\u2014a randomized, double-blind, placebo-controlled study. Cephalalgia 2004, 24:838\u2013843.","journal-title":"Cephalalgia"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1526-4637.2006.00168.x","volume":"8","author":"J.R. Saper","year":"2007","unstructured":"Saper JR, Mathew NT, Loder EW, et al.: A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 2007, 8:478\u2013485.","journal-title":"Pain Med"},{"key":"3_CR11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jpain.2006.03.002","volume":"7","author":"A.H. Elkind","year":"2006","unstructured":"Elkind AH, O\u2019Carroll P, Blumenfeld A, et al.: A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006, 7:688\u2013696.","journal-title":"J Pain"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1468-2982.2007.01315.x","volume":"27","author":"M. Relja","year":"2007","unstructured":"Relja M, Poole AC, Schoenen J, et al.: A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007, 27:492\u2013503.","journal-title":"Cephalalgia"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1526-4610.2007.00853.x","volume":"47","author":"S.K. Aurora","year":"2007","unstructured":"Aurora SK, Gawel M, Brandes JL, et al.: Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007, 47:486\u2013499.","journal-title":"Headache"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","volume":"61","author":"S.D. Silberstein","year":"2004","unstructured":"Silberstein SD, Neto W, Schmitt J, Jacobs D: Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Arch Neurol 2004, 61:490\u2013495.","journal-title":"Arch Neurol"},{"key":"3_CR15","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/WNL.58.11.1652","volume":"58","author":"F.G. Freitag","year":"2002","unstructured":"Freitag FG, Collins SD, Carlson HA, et al.: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652\u20131659.","journal-title":"Neurology"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1526-4610.2007.00949.x","volume":"48","author":"A.M. Blumenfeld","year":"2008","unstructured":"Blumenfeld AM, Schim JD, Chippendale TJ: Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008, 48:210\u2013220.","journal-title":"Headache"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp042897","volume":"354","author":"D.W. Dodick","year":"2006","unstructured":"Dodick DW: Clinical practice. Chronic daily headache. N Engl J Med 2006, 354:158\u2013165.","journal-title":"N Engl J Med"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1468-2982.2004.00641.x","volume":"24","author":"W.G. Ondo","year":"2004","unstructured":"Ondo WG, Vuong KD, Derman HS: Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004, 24:60\u201365.","journal-title":"Cephalalgia"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"N.T. Mathew","year":"2005","unstructured":"Mathew NT, Frishberg BM, Gawel M, et al.: Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293\u2013307.","journal-title":"Headache"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","volume":"45","author":"D.W. Dodick","year":"2005","unstructured":"Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315\u2013324.","journal-title":"Headache"},{"key":"3_CR21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","volume":"80","author":"S.D. Silberstein","year":"2005","unstructured":"Silberstein SD, Stark SR, Lucas SM, et al.: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126\u20131137.","journal-title":"Mayo Clin Proc"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","volume":"48","author":"F.G. Freitag","year":"2008","unstructured":"Freitag FG, Diamond S, Diamond M, Urban G: Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008, 48:201\u2013209.","journal-title":"Headache"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pain.2004.01.016","volume":"109","author":"W.J. Schulte-Mattler","year":"2004","unstructured":"Schulte-Mattler WJ, Krack P: Treatment of chronic tensiontype headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004, 109:110\u2013114.","journal-title":"Pain"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1468-2982.2006.01114.x","volume":"26","author":"S.D. Silberstein","year":"2006","unstructured":"Silberstein SD, Gobel H, Jensen R, et al.: Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26:790\u2013800.","journal-title":"Cephalalgia"},{"key":"3_CR25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1468-2982.2004.00738.x","volume":"24","author":"M. Padberg","year":"2004","unstructured":"Padberg M, de Bruijn SF, de Haan RJ, Tavy DL: Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004, 24:675\u2013680.","journal-title":"Cephalalgia"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1526-4610.2001.041007658.x","volume":"41","author":"W.J. Schmitt","year":"2001","unstructured":"Schmitt WJ, Slowey E, Fravi N, et al.: Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001, 41:658\u2013664.","journal-title":"Headache"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1526-4610.2000.00044.x","volume":"40","author":"J.D. Rollnik","year":"2000","unstructured":"Rollnik JD, Tanneberger O, Schubert M, et al.: Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000, 40:300\u2013305.","journal-title":"Headache"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1526-4610.2004.446011.x","volume":"44","author":"J.A. Pareja","year":"2004","unstructured":"Pareja JA, Pareja J, Barriga FJ, et al.: Nummular headache: a prospective series of 14 new cases. Headache 2004, 44:611\u2013614.","journal-title":"Headache"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1526-4610.2007.00960.x","volume":"48","author":"N.T. Mathew","year":"2008","unstructured":"Mathew NT, Kailasam J, Meadors L: Botulinum toxin type A for the treatment of nummular headache: four case studies. Headache 2008, 48:442\u2013447.","journal-title":"Headache"},{"issue":"Suppl1","key":"3_CR30","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","volume":"43","author":"O. Dolly","year":"2003","unstructured":"Dolly O: Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003, 43(Suppl 1):S16\u2013S24.","journal-title":"Headache"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"M. Cui","year":"2004","unstructured":"Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125\u2013133.","journal-title":"Pain"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","volume":"38","author":"M.J. Welch","year":"2000","unstructured":"Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245\u2013258.","journal-title":"Toxicon"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"21338","DOI":"10.1016\/S0021-9258(19)36614-1","volume":"267","author":"H.T. McMahon","year":"1992","unstructured":"McMahon HT, Foran P, Dolly JO, et al.: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and metenkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992, 267:21338\u201321343.","journal-title":"J Biol Chem"},{"issue":"Suppl","key":"3_CR34","first-page":"10","volume":"4","author":"M.L. Oshinsky","year":"2004","unstructured":"Oshinsky ML: Botulinum toxins and migraine: how does it work? Pract Neurol 2004, 4(Suppl):10\u201313.","journal-title":"Pract Neurol"},{"key":"3_CR35","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","volume":"28","author":"F. Antonucci","year":"2008","unstructured":"Antonucci F, Rossi C, Gianfranceschi L, et al.: Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008, 28:3689\u20133696.","journal-title":"J Neurosci"},{"key":"3_CR36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","volume":"125","author":"M. Jakubowski","year":"2006","unstructured":"Jakubowski M, McAllister PJ, Bajwa ZH, et al.: Exploding vs. imploding headache in migraine prophylaxis with Botulinum toxin A. Pain 2006, 125:286\u2013295.","journal-title":"Pain"},{"key":"3_CR37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","volume":"48","author":"N.T. Mathew","year":"2008","unstructured":"Mathew NT, Kailasam J, Meadors L: Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008, 48:194\u2013200.","journal-title":"Headache"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1526-4610.2005.05067.x","volume":"45","author":"E.J. Eross","year":"2005","unstructured":"Eross EJ, Gladstone JP, Lewis S, et al.: Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005, 45:308\u2013314.","journal-title":"Headache"},{"key":"3_CR39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1468-2982.2003.00528.x","volume":"23","author":"L. Bendtsen","year":"2003","unstructured":"Bendtsen L, Mattsson P, Zwart JA, Lipton RB: Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003, 23:487\u2013490.","journal-title":"Cephalalgia"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1468-2982.2004.00817.x","volume":"25","author":"E. Loder","year":"2005","unstructured":"Loder E, Goldstein R, Biondi D: Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005, 25:124\u2013131.","journal-title":"Cephalalgia"},{"key":"3_CR41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1468-2982.2007.01332.x","volume":"27","author":"T.J. Schwedt","year":"2007","unstructured":"Schwedt TJ, Hentz JG, Dodick DW: Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. Cephalalgia 2007, 27:528\u2013534.","journal-title":"Cephalalgia"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-009-0003-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0003-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:29:27Z","timestamp":1709620167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-009-0003-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11940-009-0003-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,8]]}}}